FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037419920> ?p ?o ?g. }

• W3037419920 endingPage "512" @default.
• W3037419920 startingPage "500" @default.
• W3037419920 abstract "Limited data exist regarding tenofovir disoproxil fumarate (TDF) safety and effectiveness in chronic hepatitis B virus-infected (CHB) patients with renal impairment (RI).To compare real-world data on renal safety and effectiveness of TDF vs entecavir (ETV) in CHB patients with moderate-to-severe RI.Retrospective, non-interventional, cohort study analysing medical records for TDF/ETV-treated CHB patients (54 European centres). Included patients experienced moderate-to-severe RI (creatinine clearance 20-60 mL/min [Cockcroft-Gault]) either before TDF/ETV initiation ('before' subgroup [baseline = treatment initiation]) or after TDF/ETV initiation ('after' subgroup [baseline = first RI occurrence]). The primary objective was TDF safety, particularly renal-related adverse events of special interest (AESI). TDF and ETV safety and effectiveness were compared and multivariate analyses were performed using inverse probability treatment weighting.'Before' subgroup included 107 TDF- and 91 ETV-treated patients; 'after' subgroup included 212 TDF- and 77 ETV-treated patients. Mean baseline creatinine clearance was higher for TDF- vs ETV-treated patients (both subgroups). Median follow-up was 3.1 years (both treatments). AESI were more frequent with TDF vs ETV ('before': 18.7% vs 8.8%; 'after': 9.9% vs 3.9%); however, differences were not significant by multivariate analysis. Only TDF-treated patients experienced renal tubular dysfunction (6.5% 'before'; 1.9% 'after') as well as renal adverse events leading to treatment discontinuation (8.4% 'before'; 7.1% 'after'). Effectiveness was similar between treatments.Overall safety was similar for TDF vs ETV (both subgroups). Given that renal tubular dysfunction occurred with TDF and not with ETV, renal safety concerns may be greater with TDF in CHB patients with RI." @default.
• W3037419920 created "2020-07-02" @default.
• W3037419920 creator A5002183213 @default.
• W3037419920 creator A5034082603 @default.
• W3037419920 creator A5050079986 @default.
• W3037419920 creator A5051349056 @default.
• W3037419920 creator A5051482861 @default.
• W3037419920 creator A5051704140 @default.
• W3037419920 creator A5063172143 @default.
• W3037419920 creator A5063340992 @default.
• W3037419920 creator A5065063010 @default.
• W3037419920 creator A5074836130 @default.
• W3037419920 creator A5081100749 @default.
• W3037419920 creator A5081349449 @default.
• W3037419920 creator A5082309779 @default.
• W3037419920 date "2020-06-25" @default.
• W3037419920 modified "2023-10-17" @default.
• W3037419920 title "Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study" @default.
• W3037419920 cites W1482153588 @default.
• W3037419920 cites W1963664285 @default.
• W3037419920 cites W1984567379 @default.
• W3037419920 cites W2007052999 @default.
• W3037419920 cites W2015015093 @default.
• W3037419920 cites W2016112916 @default.
• W3037419920 cites W2030888755 @default.
• W3037419920 cites W2037565950 @default.
• W3037419920 cites W2056599541 @default.
• W3037419920 cites W2059560167 @default.
• W3037419920 cites W2065184577 @default.
• W3037419920 cites W2076571011 @default.
• W3037419920 cites W2090738619 @default.
• W3037419920 cites W2134595040 @default.
• W3037419920 cites W2147133758 @default.
• W3037419920 cites W2164903312 @default.
• W3037419920 cites W2174723704 @default.
• W3037419920 cites W2240377523 @default.
• W3037419920 cites W2261427425 @default.
• W3037419920 cites W2294876409 @default.
• W3037419920 cites W2402419524 @default.
• W3037419920 cites W2461149013 @default.
• W3037419920 cites W2465980574 @default.
• W3037419920 cites W2521726183 @default.
• W3037419920 cites W2529757630 @default.
• W3037419920 cites W2559517093 @default.
• W3037419920 cites W2569712993 @default.
• W3037419920 cites W2578756893 @default.
• W3037419920 cites W2594410807 @default.
• W3037419920 cites W2605785536 @default.
• W3037419920 cites W2759604671 @default.
• W3037419920 cites W2782856081 @default.
• W3037419920 cites W2791839818 @default.
• W3037419920 cites W2801992343 @default.
• W3037419920 cites W2886193422 @default.
• W3037419920 cites W2891971495 @default.
• W3037419920 cites W2899878314 @default.
• W3037419920 cites W2906318256 @default.
• W3037419920 cites W2954583220 @default.
• W3037419920 cites W3007144859 @default.
• W3037419920 cites W3037419920 @default.
• W3037419920 cites W4239743462 @default.
• W3037419920 cites W935432932 @default.
• W3037419920 doi "https://doi.org/10.1111/apt.15901" @default.
• W3037419920 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7383725" @default.
• W3037419920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32583915" @default.
• W3037419920 hasPublicationYear "2020" @default.
• W3037419920 type Work @default.
• W3037419920 sameAs 3037419920 @default.
• W3037419920 citedByCount "8" @default.
• W3037419920 countsByYear W30374199202020 @default.
• W3037419920 countsByYear W30374199202021 @default.
• W3037419920 countsByYear W30374199202022 @default.
• W3037419920 countsByYear W30374199202023 @default.
• W3037419920 crossrefType "journal-article" @default.
• W3037419920 hasAuthorship W3037419920A5002183213 @default.
• W3037419920 hasAuthorship W3037419920A5034082603 @default.
• W3037419920 hasAuthorship W3037419920A5050079986 @default.
• W3037419920 hasAuthorship W3037419920A5051349056 @default.
• W3037419920 hasAuthorship W3037419920A5051482861 @default.
• W3037419920 hasAuthorship W3037419920A5051704140 @default.
• W3037419920 hasAuthorship W3037419920A5063172143 @default.
• W3037419920 hasAuthorship W3037419920A5063340992 @default.
• W3037419920 hasAuthorship W3037419920A5065063010 @default.
• W3037419920 hasAuthorship W3037419920A5074836130 @default.
• W3037419920 hasAuthorship W3037419920A5081100749 @default.
• W3037419920 hasAuthorship W3037419920A5081349449 @default.
• W3037419920 hasAuthorship W3037419920A5082309779 @default.
• W3037419920 hasBestOaLocation W30374199201 @default.
• W3037419920 hasConcept C126322002 @default.
• W3037419920 hasConcept C141071460 @default.
• W3037419920 hasConcept C159641895 @default.
• W3037419920 hasConcept C167135981 @default.
• W3037419920 hasConcept C197934379 @default.
• W3037419920 hasConcept C201903717 @default.
• W3037419920 hasConcept C203014093 @default.
• W3037419920 hasConcept C2522874641 @default.
• W3037419920 hasConcept C2776175608 @default.
• W3037419920 hasConcept C2777382497 @default.
• W3037419920 hasConcept C2777869810 @default.

• next